Literature DB >> 32407212

Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?

Nicola Fazio1.   

Abstract

Entities:  

Year:  2020        PMID： 32407212     DOI： 10.1200/JCO.20.00419

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Reply to N. Fazio.

Authors:  Eileen M O'Reilly; Wungki Park; David P Kelsen
Journal:  J Clin Oncol       Date:  2020-05-14       Impact factor: 44.544

2.  Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows in vitro and in vivo antitumor efficacy toward the treatment of nasopharyngeal cancer cells.

Authors:  Dongmei Liu; Wenguang Zhang; Xinju Liu; Rongliang Qiu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

3.  Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance.

Authors:  Joaquina Martínez-Galán; Isabel Rodriguez; Octavio Caba
Journal:  World J Gastroenterol       Date:  2021-10-21       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.